[go: up one dir, main page]

CY1123427T1 - Kpyσtaλλikeς mopφeς δiamopφωτη yποδoxea anδpoγonωn - Google Patents

Kpyσtaλλikeς mopφeς δiamopφωτη yποδoxea anδpoγonωn

Info

Publication number
CY1123427T1
CY1123427T1 CY20201100901T CY201100901T CY1123427T1 CY 1123427 T1 CY1123427 T1 CY 1123427T1 CY 20201100901 T CY20201100901 T CY 20201100901T CY 201100901 T CY201100901 T CY 201100901T CY 1123427 T1 CY1123427 T1 CY 1123427T1
Authority
CY
Cyprus
Prior art keywords
androgen receptor
pystallic
pylodoxea
mophes
andpogonon
Prior art date
Application number
CY20201100901T
Other languages
English (en)
Inventor
Anna Dilhas
Ouathek Ouerfelli
Nicholas D. Smith
Mark R. Herbert
Original Assignee
Aragon Pharmaceuticals, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=49712550&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY1123427(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Aragon Pharmaceuticals, Inc. filed Critical Aragon Pharmaceuticals, Inc.
Publication of CY1123427T1 publication Critical patent/CY1123427T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/28—Antiandrogens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Urology & Nephrology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)

Abstract

Στο παρόν περιγράφονται άμορφες και κρυσταλλικές μορφές του διαμορφωτή υποδοχέα ανδρογόνων 4-[7-(6-κυανο-5-τριφθορομεθυλοπυριδιν-3-υλο)-8-οξο-6-θειοξο-5,7-διαζασπιρο[3.4]οκτ-5-υλο]-2-φθορο-Ν-μεθυλοβενζαμίδιο. Επίσης περιγράφονται φαρμακευτικές συνθέσεις κατάλληλες για χορήγηση σε ένα θηλαστικό οι οποίες περιλαμβάνουν το διαμορφωτή υποδοχέα ανδρογόνων, και μέθοδοι χρήσης του διαμορφωτή υποδοχέα ανδρογόνων, μόνου και σε συνδυασμό με άλλες ενώσεις, για την αγωγή νόσων ή παθήσεων που σχετίζονται με την δραστικότητα του υποδοχέα ανδρογόνων.
CY20201100901T 2012-06-07 2020-09-23 Kpyσtaλλikeς mopφeς δiamopφωτη yποδoxea anδpoγonωn CY1123427T1 (el)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261656888P 2012-06-07 2012-06-07
EP13800681.2A EP2858985B1 (en) 2012-06-07 2013-06-04 Crystalline forms of an androgen receptor modulator
PCT/US2013/044116 WO2013184681A1 (en) 2012-06-07 2013-06-04 Crystalline forms of an androgen receptor modulator

Publications (1)

Publication Number Publication Date
CY1123427T1 true CY1123427T1 (el) 2021-12-31

Family

ID=49712550

Family Applications (4)

Application Number Title Priority Date Filing Date
CY20181100712T CY1120393T1 (el) 2012-06-07 2018-07-06 Κρυσταλλικες μορφες διαμορφωτη υποδοχεα ανδρογονων
CY20201100901T CY1123427T1 (el) 2012-06-07 2020-09-23 Kpyσtaλλikeς mopφeς δiamopφωτη yποδoxea anδpoγonωn
CY20211100595T CY1124831T1 (el) 2012-06-07 2021-07-02 Κρυσταλλiκες μορφες διαμορφωτη υποδοχεα ανδρογονων
CY2021032C CY2021032I2 (el) 2012-06-07 2021-11-04 Κρυσταλλiκες μορφες διαμορφωτη υποδοχεα ανδρογονων

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CY20181100712T CY1120393T1 (el) 2012-06-07 2018-07-06 Κρυσταλλικες μορφες διαμορφωτη υποδοχεα ανδρογονων

Family Applications After (2)

Application Number Title Priority Date Filing Date
CY20211100595T CY1124831T1 (el) 2012-06-07 2021-07-02 Κρυσταλλiκες μορφες διαμορφωτη υποδοχεα ανδρογονων
CY2021032C CY2021032I2 (el) 2012-06-07 2021-11-04 Κρυσταλλiκες μορφες διαμορφωτη υποδοχεα ανδρογονων

Country Status (45)

Country Link
US (9) US9481663B2 (el)
EP (4) EP3922629A1 (el)
JP (3) JP6182209B2 (el)
KR (2) KR102195916B1 (el)
CN (3) CN113135892A (el)
AU (3) AU2013271751B2 (el)
BR (1) BR112014030678A2 (el)
CA (4) CA3008345C (el)
CL (1) CL2014003331A1 (el)
CO (1) CO7240407A2 (el)
CR (2) CR20190331A (el)
CY (4) CY1120393T1 (el)
DK (3) DK3533792T3 (el)
EA (3) EA033956B1 (el)
EC (1) ECSP14030098A (el)
ES (3) ES2670683T3 (el)
FR (1) FR21C1050I2 (el)
GT (1) GT201400283A (el)
HK (2) HK1210175A1 (el)
HR (3) HRP20180902T1 (el)
HU (4) HUE038082T2 (el)
IL (4) IL236055A0 (el)
IN (1) IN2014DN10084A (el)
LT (4) LT2858985T (el)
LU (1) LUC00236I2 (el)
ME (2) ME03815B (el)
MX (1) MX356754B (el)
MY (1) MY187500A (el)
NI (1) NI201400142A (el)
NL (1) NL301144I2 (el)
NO (1) NO2021046I1 (el)
NZ (2) NZ702203A (el)
PE (2) PE20150631A1 (el)
PH (2) PH12014502714B1 (el)
PL (3) PL3348553T3 (el)
PT (3) PT3348553T (el)
RS (3) RS57370B1 (el)
SG (3) SG10201610248SA (el)
SI (3) SI2858985T1 (el)
SM (3) SMT201800311T1 (el)
TR (1) TR201808939T4 (el)
TW (1) TWI532732B (el)
UA (2) UA115665C2 (el)
WO (1) WO2013184681A1 (el)
ZA (1) ZA201500076B (el)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8461343B2 (en) 2007-03-27 2013-06-11 Sloan-Kettering Institute For Cancer Research Synthesis of thiohydantoins
US9574043B2 (en) 2009-01-12 2017-02-21 University Of Massachusetts Lowell Polyisobutylene-based polyurethanes
AU2012353660A1 (en) 2011-12-16 2014-06-12 Olema Pharmaceuticals, Inc. Novel benzopyran compounds, compositions and uses thereof
JP6182209B2 (ja) 2012-06-07 2017-08-16 アラゴン ファーマシューティカルズ，インコーポレイテッド アンドロゲン受容体変調剤の結晶質形態
CN105358535B (zh) 2012-09-11 2019-01-04 麦迪威森前列腺医疗有限责任公司 恩杂鲁胺制剂
EA037806B1 (ru) 2012-09-26 2021-05-24 Арагон Фармасьютикалз, Инк. Способ лечения неметастатического кастрационно-резистентного рака простаты
WO2014081916A2 (en) 2012-11-21 2014-05-30 University Of Massachusetts High strength polyisobutylene polyurethanes
JOP20200097A1 (ar) * 2013-01-15 2017-06-16 Aragon Pharmaceuticals Inc معدل مستقبل أندروجين واستخداماته
JP2017525727A (ja) * 2014-08-26 2017-09-07 アスター バイオテック リミテッド ライアビリティ カンパニー プロテインキナーゼ阻害剤
WO2016090105A1 (en) 2014-12-05 2016-06-09 Aragon Pharmaceuticals, Inc. Anticancer compositions
SG11201704267VA (en) 2014-12-05 2017-06-29 Aragon Pharmaceuticals Inc Anticancer compositions
MA41108B1 (fr) 2014-12-05 2021-03-31 Aragon Pharmaceuticals Inc Compositions anticancéreuses
CN107113952B (zh) 2014-12-19 2019-08-27 路创技术有限责任公司 具有多个发光二极管驱动器的多通道照明器具
AR108489A1 (es) 2016-06-03 2018-08-29 Aragon Pharmaceuticals Inc Composiciones antineoplásicas
ES2952770T3 (es) 2016-12-13 2023-11-06 Watson Lab Inc Formas de estado sólido de apalutamida
US10526429B2 (en) 2017-03-07 2020-01-07 Cardiac Pacemakers, Inc. Hydroboration/oxidation of allyl-terminated polyisobutylene
US10835638B2 (en) 2017-08-17 2020-11-17 Cardiac Pacemakers, Inc. Photocrosslinked polymers for enhanced durability
SG11202003402QA (en) 2017-10-16 2020-05-28 Aragon Pharmaceuticals Inc Anti-androgens for the treatment of non-metastatic castration-resistant prostate cancer
WO2019135254A1 (en) 2018-01-02 2019-07-11 Mylan Laboratories Limited Apalutamide polymorphs and their preparation thereof
WO2019143629A1 (en) 2018-01-17 2019-07-25 Cardiac Pacemakers, Inc. End-capped polyisobutylene polyurethane
CN111344283B (zh) * 2018-06-20 2022-08-12 苏州科睿思制药有限公司 Arn-509的晶型及其制备方法和用途
WO2020049598A2 (en) 2018-09-08 2020-03-12 Cipla Limited Apalutamide polymorphs
IT201900003839A1 (it) 2019-03-15 2020-09-15 Olon Spa Sintesi di apalutamide amorfa stabile
WO2020234817A1 (en) * 2019-05-21 2020-11-26 Laurus Labs Limited Polymorphic forms of apalutamide and its preparation thereof
IT201900010593A1 (it) 2019-07-01 2021-01-01 Dipharma Francis Srl Forma cristallina di un inibitore di recettori degli androgeni
EP4017848A1 (en) * 2019-08-22 2022-06-29 Dr. Reddy's Laboratories Ltd. Process for the preparation of apalutamide
IT201900015974A1 (it) 2019-09-10 2021-03-10 Olon Spa Apalutamide cristallina stabile in forma pura e processo per la sua preparazione
CN110590740A (zh) * 2019-09-20 2019-12-20 武汉大学 一种阿帕鲁胺化合物及其药物制剂
US20230312507A1 (en) 2020-09-04 2023-10-05 Synthon B.V. Improved process for preparation of apalutamide
WO2023143090A1 (zh) * 2022-01-25 2023-08-03 成都苑东生物制药股份有限公司 一种阿帕他胺溶剂化物新晶型及其制备方法
CN115536634B (zh) * 2022-10-17 2024-06-11 上海博悦生物科技有限公司 一种阿帕他胺的合成方法
CN116332907A (zh) * 2023-03-16 2023-06-27 奥锐特药业股份有限公司 一种无定形阿帕他胺的制备方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5323907A (en) 1992-06-23 1994-06-28 Multi-Comp, Inc. Child resistant package assembly for dispensing pharmaceutical medications
US7709517B2 (en) * 2005-05-13 2010-05-04 The Regents Of The University Of California Diarylhydantoin compounds
CN101032483B (zh) 2006-03-09 2011-05-04 陈德桂 调节雄激素受体活性的乙内酰脲衍生物及其应用
EP2656842B1 (en) 2006-03-27 2016-08-10 The Regents of The University of California Androgen receptor modulator for the treatment of prostate cancer and androgen receptor-associated diseases
CN102755318B (zh) * 2006-03-29 2014-09-10 加利福尼亚大学董事会 二芳基硫代乙内酰脲化合物
US8461343B2 (en) 2007-03-27 2013-06-11 Sloan-Kettering Institute For Cancer Research Synthesis of thiohydantoins
BR112012020558B1 (pt) * 2010-02-16 2020-11-03 Aragon Pharmaceuticals, Inc moduladores do receptor de androgênio, suas composições farmacêuticas, e seus usos
JP6182209B2 (ja) * 2012-06-07 2017-08-16 アラゴン ファーマシューティカルズ，インコーポレイテッド アンドロゲン受容体変調剤の結晶質形態
CN111344283B (zh) 2018-06-20 2022-08-12 苏州科睿思制药有限公司 Arn-509的晶型及其制备方法和用途

Also Published As

Publication number Publication date
PH12016501470A1 (en) 2017-07-10
US10556882B2 (en) 2020-02-11
CN104619692A (zh) 2015-05-13
US20150133481A1 (en) 2015-05-14
PL3348553T3 (pl) 2021-02-08
CR20140549A (es) 2015-04-06
PE20150631A1 (es) 2015-05-11
TR201808939T4 (tr) 2018-07-23
EP3533792B1 (en) 2021-05-05
IL275413A (en) 2020-07-30
ES2670683T3 (es) 2018-05-31
HUE050357T2 (hu) 2020-11-30
DK2858985T3 (en) 2018-05-28
ES2875932T3 (es) 2021-11-11
KR102062024B1 (ko) 2020-01-03
SMT202000496T1 (it) 2020-11-10
EP3922629A1 (en) 2021-12-15
US9994545B2 (en) 2018-06-12
CA2875767A1 (en) 2013-12-12
EP2858985A1 (en) 2015-04-15
SI2858985T1 (sl) 2018-12-31
MX2014015005A (es) 2015-09-04
TW201402561A (zh) 2014-01-16
CA3008345C (en) 2019-10-22
BR112014030678A2 (pt) 2017-06-27
HUE038082T2 (hu) 2018-09-28
FR21C1050I1 (fr) 2021-12-10
UA115665C2 (uk) 2017-12-11
CA2875767C (en) 2018-08-14
PL3533792T3 (pl) 2021-11-29
CY1124831T1 (el) 2022-03-24
US20190241539A1 (en) 2019-08-08
SMT202100355T1 (it) 2021-07-12
AU2013271751B2 (en) 2017-02-23
SG10201610248SA (en) 2017-02-27
IL259738B (en) 2021-06-30
ZA201500076B (en) 2016-10-26
PH12016501470B1 (en) 2021-12-10
SI3348553T1 (sl) 2020-11-30
ME03815B (me) 2021-04-20
JP6182209B2 (ja) 2017-08-16
US12018008B2 (en) 2024-06-25
NO2021046I1 (no) 2021-11-02
JP2017178923A (ja) 2017-10-05
PT3533792T (pt) 2021-06-07
ECSP14030098A (es) 2016-01-29
EA201791592A1 (ru) 2018-01-31
LT3533792T (lt) 2021-07-26
US10308630B2 (en) 2019-06-04
CN113135892A (zh) 2021-07-20
US20200354335A1 (en) 2020-11-12
CR20190331A (es) 2019-11-12
NZ702203A (en) 2016-09-30
PL2858985T3 (pl) 2018-09-28
HK1210175A1 (en) 2016-04-15
MY187500A (en) 2021-09-24
PH12014502714A1 (en) 2015-02-02
HRP20210909T1 (hr) 2021-09-03
IL267608A (en) 2019-08-29
EA028791B1 (ru) 2017-12-29
US9481663B2 (en) 2016-11-01
US20250092011A1 (en) 2025-03-20
CA3114726A1 (en) 2013-12-12
EP2858985B1 (en) 2018-04-18
HK1226066A1 (zh) 2017-09-22
KR102195916B1 (ko) 2020-12-30
IN2014DN10084A (el) 2015-08-21
IL259738A (en) 2018-07-31
NZ717683A (en) 2018-04-27
AU2017279807B2 (en) 2018-11-08
CY2021032I2 (el) 2022-03-24
JP2015518890A (ja) 2015-07-06
JP6345821B2 (ja) 2018-06-20
LUC00236I2 (el) 2025-02-03
CL2014003331A1 (es) 2016-03-04
HRP20180902T1 (hr) 2018-08-24
JP2018141009A (ja) 2018-09-13
US20190330182A1 (en) 2019-10-31
HRP20201387T1 (hr) 2020-11-27
SG10201610249TA (en) 2017-02-27
AU2013271751A1 (en) 2014-12-18
EP3348553B1 (en) 2020-07-08
KR20190132543A (ko) 2019-11-27
NI201400142A (es) 2016-12-02
US10934271B2 (en) 2021-03-02
US20210163441A1 (en) 2021-06-03
AU2017279807A1 (en) 2018-01-25
EA201992010A1 (ru) 2020-01-24
UA123142C2 (uk) 2021-02-24
CA3008345A1 (en) 2013-12-12
KR20150021993A (ko) 2015-03-03
SMT201800311T1 (it) 2018-07-17
HUS2100047I1 (hu) 2021-11-29
RS57370B1 (sr) 2018-08-31
SG11201408140QA (en) 2015-01-29
CO7240407A2 (es) 2015-04-17
EP3348553A1 (en) 2018-07-18
AU2017200298B2 (en) 2017-09-28
SI3533792T1 (sl) 2021-11-30
EA033956B1 (ru) 2019-12-13
PH12014502714B1 (en) 2015-02-02
CN105693692A (zh) 2016-06-22
PT3348553T (pt) 2020-09-28
PT2858985T (pt) 2018-07-10
US20180258067A1 (en) 2018-09-13
DK3348553T3 (da) 2020-07-27
EP3533792A1 (en) 2019-09-04
US10766875B2 (en) 2020-09-08
US20170001977A1 (en) 2017-01-05
IL236055A0 (en) 2015-02-01
CA3055660A1 (en) 2013-12-12
EA201492272A1 (ru) 2015-05-29
RS60617B1 (sr) 2020-09-30
WO2013184681A1 (en) 2013-12-12
LTPA2021525I1 (el) 2021-11-25
CY2021032I1 (el) 2022-03-24
ES2809738T3 (es) 2021-03-05
CY1120393T1 (el) 2019-07-10
AU2017200298A1 (en) 2017-02-02
HUE054595T2 (hu) 2021-09-28
DK3533792T3 (da) 2021-06-28
US10526310B2 (en) 2020-01-07
LT2858985T (lt) 2018-09-25
RS61988B1 (sr) 2021-07-30
NL301144I2 (nl) 2025-03-20
US20200115361A1 (en) 2020-04-16
ME03081B (me) 2019-01-20
MX356754B (es) 2018-06-11
EP2858985A4 (en) 2016-05-25
PE20200725A1 (es) 2020-07-21
TWI532732B (zh) 2016-05-11
GT201400283A (es) 2017-07-03
FR21C1050I2 (fr) 2024-05-24
LT3348553T (lt) 2020-09-25

Similar Documents

Publication Publication Date Title
CY1123427T1 (el) Kpyσtaλλikeς mopφeς δiamopφωτη yποδoxea anδpoγonωn
CY1121511T1 (el) Ενωσεις και μεθοδοι για διαμορφωση κινασων και ενδειξεις αυτων
CY1122730T1 (el) 1,2,4-τριαζολες ως διαμορφωτες πυρηνικης μεταφορας και χρησεις αυτων
CR20120591A (es) Derivados de aminopirimidina como moduladores de la lrrk2
UY35678A (es) SALES DE DERIVADOS DE 2-AMINO-1-HIDROXIETIL-8-HIDROXIQUINOLIN-2(1H)-ONA QUE TIENEN ACTIVIDAD ANTAGO NISTA DE RECEPTORES MUSCARÍNICOS ASÍ COMO ACTIVIDAD AGONISTA DEL RECEPTOR ß2 ADRENÉRGICO
CY1120159T1 (el) Ενωσεις που εχουν δραστικοτητα ανταγωνιστη μουσκαρινικου υποδοχεα και αγωνιστη βητα2 αδρενεργικου υποδοχεα
BR112015020389A2 (pt) compostos carbazol úteis como inibidores de bromodomínio
UY35177A (es) Novedosos derivados de bencimidazol como antagonistas de ep4
UY35675A (es) Derivados sustituidos de quinazolin-4-ona
ECSP12012083A (es) Pirrolidina-2-carboxamidas sustituidas
CY1117745T1 (el) Ετεροκυκλικες ενωσεις και χρηση αυτων ως ρυθμιστες υποδοχεα τυπου iii κινασων τυροσινης
GT201500159A (es) Derivados de imidazopiridazina como moduladores del receptor gabaa
SV2017005381A (es) Compuestos de imidazopiridazina
MX376113B (es) Derivados de azabenzimidazoles como moduladores del receptor ampa, y el uso de los mismos en el tratamiento de enfermedades asociadas con los receptores ampa.
DOP2014000114A (es) Nuevos 2h–indazoles como antagonistas del receptor ep2
GT201300304A (es) 1-piperazino-3-fenil-indanos deuterados para el tratamiento de esquizofrenia
GT201600004A (es) Nueva sal de la 3-[(3-{[4-(4-morfolinilmetil)-1h- pirrol-2-il]metilen}-2-oxo-2,3-dihidro-1h-indol-5-il)metil]-1,3-tiazolidina-2,4-diona, su preparación, y las formulaciones farmacéuticas que la contienen
EA201690236A1 (ru) Производные индол-3-карбинола
ECSP099644A (es) Derivados de quinolina, composiciones farmacéuticas que los comprenden y el uso de tales en el tratamiento de enfermedades del sistema nervioso central y periférico
ECSP12012120A (es) Compuestos de pirazol como antagonistas de crth2.
CR20120083A (es) Derivados de oxazina y su uso en el tratamiento de los trastornos neurologicos
CU24047B1 (es) Derivados de oxazina útiles en el tratamiento de los trastornos neurológicos
TR201106009A2 (tr) Sefalosporin türevinin farmasötik bir bileşim içerisinde kullanımı.
TR201106004A2 (tr) Sefalosporin türevinin farmasotik bir bileşim içerisinde kullanımı.